Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Table 1

The main characteristics of six eligible RCTs.

Trials	Treatments	Chemotherapy	No. of patients experiment control		OS (m)	HR for OS	PFS (m)	HR for PFS	ORR	≥3 TRAEs	PD-L1 detection
KEYNOTE-590 (ESCC) NCT03189719	Pembrolizumab	Cisplatin + fluorouracil	274	274	12.6 vs. 9.8	HR 0.72 (95% CI 0.60–0.88)	6.3 vs. 5.8	HR 0.65 (95% CI 0.54–0.78)	—	—	22C3
CheckMate 648 NCT03143153	Nivolumab	Cisplatin + fluorouracil	321	324	13.2 vs. 10.7	HR 0.74 (95% CI 0.61–0.89)	5.8 vs. 5.6	HR 0.81 (98.5% CI 0.64–1.04)	47.3% vs. 26.9%	49.0% vs. 37.5%	28–8
ORIENT-15 NCT03748134	Sintilimab	(1) Cisplatin + fluorouracil	327	332	16.7 vs. 12.5	HR 0.63 (95% CI 0.51–0.78)	7.2 vs. 5.7	HR 0.56 (95% CI 0.46–0.68)	66.1% vs. 45.5%	59.9% vs. 54.5%	22C3
		(2) Cisplatin + paclitaxel
ESCORT-1st NCT03691090	Camrelizumab	Cisplatin + paclitaxel	298	298	15.3 vs. 12.0	HR 0.70 (95% CI 0.56–0.88)	6.9 vs. 5.6	HR 0.56 (95% CI 0.46–0.68)	72.1% vs. 62.1%	63.4% vs. 67.7%	6E8
JUPITER-06 NCT03829969	Toripalimab	Cisplatin + paclitaxel	257	257	17.0 vs. 11.0	HR 0.58 (95% CI 0.43–0.78)	5.7 vs. 5.5	HR 0.58 (95% CI 0.46–0.74)	69.3% vs. 52.1%	64.6% vs. 56.0%	JS311
RATIONALE-306 NCT03783442	Tislelizumab	(1) Platinum + fluoropyrimidine	326	323	17.2 vs. 10.6	HR 0.66 (95% CI 0.54–0.80)	7.3 vs. 5.6	HR 0.62 (95% CI 0.52–0.75)	63.5% vs. 42.4%	66.7% vs. 64.5%	SP263
		(2) Platinum + paclitaxel

RCTs: randomized controlled trials; ESCC: esophageal squamous cell carcinoma; OS: overall survival; HR: hazard ratio; PFS: progression-free survival; ORR: objective response rate; TRAEs: treatment-related adverse events; PD-L1: programmed cell death ligand 1.